HOUSTON, Aug. 26, 2020 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary aesthetic platform technology,
today announced the company has initiated the tooling production
for the improved cartridge in its RAP device. The company has
issued orders for all of the tooling components, which will allow
for production at scale of the new cartridge design. The new
tooling is expected to be complete by mid-September.
As previously announced, the new cartridge in the RAP device
includes improved features providing ease of use and a more
user-friendly experience. The improved device features
automatically inserting and ejecting cartridges, a system to detect
counterfeit cartridges, and a method of automatic adjustment of the
electrode resulting in longer cartridge life.
Join our more than 200K
subscribers here to follow the
Company: https://soly-investors.com
"This is a critical initial step for the Company to be able to
have the product manufactured at scale and should provide for the
availability of the improved product for our upcoming launch," said
Christopher Capelli, MD, founder,
President and CEO of Soliton. "Furthermore, this investment is a
key element that we believe will provide the opportunity to improve
our margins through cost reduction. We believe that our revised
launch plan, and the improved design and function of our product,
will enable us to come to market at an optimal time, with an
optimal device."
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson
Cancer Center. The Company's first FDA cleared commercial product
will use rapid pulses of acoustic shockwaves as an accessory to
lasers for the removal of unwanted tattoos. The Company is based in
Houston, Texas, and is actively
engaged in bringing the Rapid Acoustic Pulse ("RAP") device to the
market. The Company believes this "Soliton" method has the
potential to lower tattoo removal costs for patients, while
increasing profitability to practitioners, compared to current
laser removal methods. Soliton has completed a clinical study
using the RAP device to improve the appearance of cellulite and is
investigating potential additional capabilities of the RAP
technology. The device is currently cleared in the United States only for use in tattoo
removal and is not yet cleared for use to address cellulite.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, which statements involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability to complete the
manufacturing of the tooling, the potential for the tooling to
generate cost savings, and the ability of the Company to scale up
production quantities. These statements relate to future events,
future expectations, plans and prospects. Although Soliton believes
that the expectations reflected in such forward-looking statements
are reasonable as of the date made, actual results or outcomes may
prove to be materially different from the expectations expressed or
implied by such forward-looking statements. Soliton has attempted
to identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' "would," ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
in our filings with the Securities and Exchange Commission ("SEC"),
including under the heading " Risk Factors" in the Form 10-K for
year ended December 31, 2019 filed
with the SEC and as updated in our Form 10-Q filings and in our
other filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-initiates-new-tooling-production-process-for-improved-cartridge-in-rap-device-301118514.html
SOURCE Soliton, Inc.